# FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.

Source: https://onco.cc/trials/nct07515963/  
OnCo record `nct07515963` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Zhongnan Hospital, not yet recruiting.

## Summary

FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. is a phase 2, interventional study registered as NCT07515963 by Zhongnan Hospital, with a registry enrolment figure of 24 participants, started 2026-06-01 and due to reach its primary completion in 2027-02-01. Interventions recorded: FULIRI combination targeted therapy. Conditions listed: Colo-rectal Cancer. Primary outcome: Objective Response Rate (ORR). Colorectal eligibility wording from the registry: "\- (1) Age 18-75 years; (2) Histologically confirmed colorectal adenocarcinoma; (3) Synchronous liver metastasis of colorectal cancer, or liver metastasis occurring after curative surgery for colorectal cancer, and no prior systemic anti-tumor treatment (including but not limited to systemic chemoth". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07515963
- Phase: 2
- Setting: A Phase II Clinical Study of FULIRI Regimen Chemotherapy Combined With Targeted Therapy for First-line Conversion Treatment of Colorectal Cancer Liver Metastases.
- Sponsor: Zhongnan Hospital
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT07515963: https://clinicaltrials.gov/study/NCT07515963

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07515963.json